Chiasma, Inc. (CHMA) |
| 3.76 -0.24 (-6%) 04-24 15:47 |
| Open: | 4.08 |
| High: | 4.1 |
| Low: | 3.76 |
| Volume: | 8,196,718 |
| Market Cap: | 0(M) |
| PE Ratio: | -2.39 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 12.00 |
| Resistance 1: | 10.27 |
| Pivot price: | 10.18 |
| Support 1: | 10.19 |
| Support 2: | 10.14 |
| 52w High: | 5.74 |
| 52w Low: | 2.77 |
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
Financials
| EPS | 0.000 |
| Book Value | -0.380 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Mon, 28 Nov 2022
Mpm Asset Management Investors Bv4 Llc Net Worth (2026) - GuruFocus
Tue, 12 Jul 2022
SpyBiotech Appoints Mark Leuchtenberger as Chief Executive Officer - citybiz
Tue, 27 Jul 2021
Pulmatrix Appoints Director Anand Varadan - citybiz
Wed, 05 May 2021
Chiasma to Merge with Amryt - citybiz
Wed, 05 May 2021
Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases - GlobeNewswire
Mon, 29 Jun 2020
Chiasma wins FDA approval for acromegaly treatment - Globes - Israel Business News
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
